Online citations, reference lists, and bibliographies.

Population Pharmacokinetics Of Pomalidomide In Patients With Relapsed Or Refractory Multiple Myeloma With Various Degrees Of Impaired Renal Function

Yan Li, Xiao-Min Wang, Edward O'Mara, Meletios Athanasios Dimopoulos, Pieter Sonneveld, Katja Christina Weisel, Jeffrey V. Matous, David S Siegel, Jatin J. Shah, Elisabeth Kueenburg, Lars Sternas, Chloe Cavanaugh, Mohamed Zaki, Maria Palmisano, Simon Zhou
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Pomalidomide is an immunomodulatory drug for treatment of relapsed or refractory multiple myeloma (rrMM) in patients who often have comorbid renal conditions. To assess the impact of renal impairment on pomalidomide exposure, a population pharmacokinetics (PPK) model of pomalidomide in rrMM patients with various degrees of impaired renal function was developed. Intensive and sparse pomalidomide concentration data collected from two clinical studies in rrMM patients with normal renal function, moderately impaired renal function, severely impaired renal function not requiring dialysis, and with severely impaired renal function requiring dialysis were pooled over the dose range of 2 to 4 mg, to assess specifically the influence of the impaired renal function as a categorical variable and a continuous variable on pomalidomide clearance and plasma exposure. In addition, pomalidomide concentration data collected on dialysis days from both the withdrawal (arterial) side and from the returning (venous) side of the dialyzer, from rrMM patients with severely impaired renal function requiring dialysis, were used to assess the extent to which dialysis contributes to the removal of pomalidomide from blood circulation. PPK analyses demonstrated that moderate to severe renal impairment not requiring dialysis has no influence on pomalidomide clearance or plasma exposure, as compared to those patients with normal renal function, while pomalidomide exposure increased approximately 35% in patients with severe renal impairment requiring dialysis on nondialysis days. In addition, dialysis increased total body pomalidomide clearance from 5 L/h to 12 L/h, indicating that dialysis will significantly remove pomalidomide from the blood circulation. Thus, pomalidomide should be administered post-dialysis on the days of dialysis.
This paper references
10.7326/0003-4819-130-6-199903160-00002
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Andrew S. Levey (1999)
MM-013 phase 2 multicenter study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and renal impairment
P Sonneveld (2017)
10.1007/s00280-011-1760-3
Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects
Nianhang Chen (2011)
10.1016/j.leukres.2014.06.015
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Naval Daver (2014)
10.1016/j.mvr.2008.08.003
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Ling Lu (2009)
10.1158/0008-5472.CAN-06-2317
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Dominique Verhelle (2007)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Laura G. Corral (1999)
Imnovid (pomalidomide)
Azienda Ospedaliera Arcispedale Santa Maria Nuova/ IRCCS
Comitato Etico Provinciale Di Reggio Emilia
10.1159/000180580
Prediction of creatinine clearance from serum creatinine.
Donald W. Cockcroft (1975)
10.1002/chir.10221
Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.
Steve K. Teo (2003)
10.7326/0003-4819-150-9-200905050-00006
A new equation to estimate glomerular filtration rate.
Andrew S. Levey (2009)
10.1177/0091270007309563
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Nianhang Chen (2007)
10.1002/jcph.455
Population Pharmacokinetics of Pomalidomide
Yan Li (2015)
10.2169/internalmedicine.54.4075
Dose-adjusted Lenalidomide Combined with Low-dose Dexamethasone Rescues Older Patients with Bortezomib-resistant Multiple Myeloma.
Satoshi Yamasaki (2015)
Segreteria Tecnico Scientifica ed Amministrativa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Palazzo Uffici, Via F. Sforza n
10.1007/s00262-008-0512-7
Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
Dan Zhu (2008)
10.1182/blood.V96.9.2943
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima (2000)
Pomalidomide PK in patients with relapsed or refractory multiple myeloma
10.1111/j.1365-2141.2004.05286.x
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Toshiaki Hayashi (2005)
10.1007/s00280-012-2040-6
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
Matthew C. Hoffmann (2012)
MM-013 phase 2 multicenter study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and renal impairment (RI)
P Sonneveld (2017)
10.1111/J.1365-2141.2007.06841.X
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
N. Varsha Monica Reddy (2008)
Stationsstraat 9, 9401 KV Assen, the Netherlands 601 CEIC Área de Salud de Salamanca
10.1182/blood-2013-11-538835
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Paul G Richardson (2014)
Pomalyst (pomalidomide)
(2016)
Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, England 801 Ethics Committee of the City of Vienna
10.1016/S1470-2045(13)70380-2
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Jesús F. San Miguel (2013)
10.1038/sj.leu.2402295
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
D Gupta (2001)
10.1182/blood.V99.12.4525
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Nicholas Mitsiades (2002)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar